Apraglutide, a novel glucagon‐like peptide‐2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo‐controlled, randomized phase 2 trial
Johanna Eliasson, Mark Hvistendahl, Nanna Freund, Federico Bolognani, Christian Meyer, Palle Bekker Jeppesen
Journal of Parenteral and Enteral Nutrition
Abstract
Once-weekly apraglutide was well tolerated at both tested doses and significantly increased urine volume output, providing evidence for increased intestinal fluid absorption. A phase 3 trial is underway in adults with SBS-IF.
Extracted Claims
2 claims extracted from this paper into the knowledge graph
apraglutide provided evidence for increased intestinal fluid absorption
“Once-weekly apraglutide was well tolerated at both tested doses and significantly increased urine volume output, providing evidence for increased intestinal fluid absorption.”
apraglutide increased urine volume output
“Once-weekly apraglutide was well tolerated at both tested doses and significantly increased urine volume output, providing evidence for increased intestinal fluid absorption.”